Femasys (FEMY) reported second-quarter 2026 sales of $331,827, down 18.9% from $409,268 a year earlier. Net loss was $4.47 million, or $1.33 per basic and diluted share, compared with a $4.59 million loss, or $3.18 per share, in the prior-year quarter.
The company said it completed a $30 million private placement, with potential proceeds of up to $90 million upon full cash exercise of warrants. Femasys also reported the launch of FemaSeed Complete at ACOG 2026 and initial commercial use of the product.
- Six-month sales rose 0.8% to $756,716.
- Second-quarter research and development expense increased 37.6% to $1.95 million.
- Cash and cash equivalents were approximately $1.4 million as of June 30, 2026.
- Femasys regained compliance with Nasdaq listing requirements and named John Canning chief operating officer.
- The company received CE Mark approval for its FemHSG Catheter and formed a partnership with AMI Technologies to commercialize its fertility portfolio in Israel.
$FEMY Insider Trading Activity
$FEMY insiders have traded $FEMY stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FEMY stock by insiders over the last 6 months:
- DOV ELEFANT (Chief Financial Officer) purchased 15,625 shares for an estimated $50,000
- KATHY LEE-SEPSICK (Chief Executive Officer) purchased 15,625 shares for an estimated $50,000
- JOHN CHARLES CANNING (Chief Operating Officer) purchased 4,375 shares for an estimated $14,000
- JEREMY ALEXANDER SIPOS (Chief Technology Officer) purchased 3,125 shares for an estimated $10,000
- JEFFREY GERALD MIFEK (Chief Clinical-Medical Affairs) purchased 3,125 shares for an estimated $10,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$FEMY Hedge Fund Activity
We have seen 8 institutional investors add shares of $FEMY stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 1,867,987 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,808,185
- CITADEL ADVISORS LLC removed 342,166 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $143,778
- JANE STREET GROUP, LLC removed 74,727 shares (-69.8%) from their portfolio in Q1 2026, for an estimated $31,400
- TWO SIGMA INVESTMENTS, LP removed 26,141 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $10,984
- TWO SIGMA SECURITIES, LLC removed 16,294 shares (-52.3%) from their portfolio in Q1 2026, for an estimated $6,846
- UBS GROUP AG added 15,681 shares (+506.5%) to their portfolio in Q2 2026, for an estimated $65,546
- GIBBS WEALTH MANAGEMENT added 12,100 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
